Clinical trials: SARS-CoV 2
COVID-19, SARS-CoV 2
Efficacy of Intravenous Melatonin on Mortality in Adult Patients Admitted to the Intensive Care Unit With COVID-19
There is an urgent need to evaluate effective treatments for COVID-19 patients. Melatonin has significant anti-inflammatory and antioxidant properties and it lacks of side-effects.
- Conditions
- COVID-19, SARS-CoV 2, Coronavirus Infection
- Trial name
- MELCOVID (NCT04568863)
- Testing
- Melatonin intravenous
- Where
- Spain
- Volunteers
- 18 people
- Sponsor
- Pharmamel S.L.
COVID-19, SARS-CoV 2
Inhaled NO for the Treatment of COVID-19 Caused by SARS-CoV-2 (CANADA Trial)
The purpose of this open label, 2-phase, study is to obtain information on the safety of 80 ppm and the safety and efficacy of 150 ppm Nitric Oxide given in addition to the standard of care of patients with COVID-19 caused by…
- Conditions
- COVID-19, SARS-CoV 2, Respiratory Disease, Pneumonia, Viral
- Trial name
- NCT04456088
- Testing
- 150 ppm Nitric Oxide delivered through LungFit Delivery System, 80 ppm Nitric Oxide delivered through LungFit Delivery System
- Sponsor
- Beyond Air Inc.
SARS-CoV 2, COVID-19
Masitinib Combined With Isoquercetin and Best Supportive Care in Hospitalized Patients With Moderate and Severe COVID-19
Study objective is to evaluate the efficacy of the combination of masitinib and isoquercetin in adult hospitalized patients with moderate and severe COVID-19.
- Conditions
- SARS-CoV 2, COVID-19, Coronavirus Disease 2019
- Trial name
- NCT04622865
- Testing
- Masitinib, Isoquercetin, Best Supportive Care
- Where
- 6 sites in France
- Volunteers
- 200 people
- Sponsor
- AB Science
Coronavirus Infections, SARS-CoV 2
Use of Hydroxychloroquine Alone or Associated for Inpatients With SARS-CoV2 Virus (COVID-19)
The Severe Acute Respiratory Syndrome CoronaVirus 2 (SARS-CoV2) has been identified in Wuhan, China, which causes severe pulmonary complications and flu syndrome, which has spread rapidly to all continents.
- Conditions
- Coronavirus Infections, SARS-CoV 2, SARS (Severe Acute Respiratory Syndrome), Pulmonary Disease
- Trial name
- NCT04361461
- Testing
- Hydroxychloroquine Sulfate, Hydroxychloroquine Sulfate + Azythromycin
- Where
- Brazil
- Sponsor
- Apsen Farmaceutica S.A.
SARS CoV 2 Infection
Multicenter Double Blind, Parallel-group Phase 2/3 Trial, to Study Raloxifene in Adult COVID-19 Patients.
The objective of the study is to evaluate the efficacy and safety of two different doses of raloxifene orally administered compared to placebo in patients with early diagnosis of paucisymptomatic COVID-19.
- Trial name
- NCT05172050
- Testing
- Raloxifene
- Where
- 11 sites in France, Italy and 1 more
- Volunteers
- 61 people
- Sponsor
- Dompé Farmaceutici S.p.A
COVID-19, Corona Virus Infection
A Phase II, Controlled Clinical Study Designed to Evaluate the Effect of ArtemiC in Patients Diagnosed With COVID-19
Agent Name and Study Duration ArtemiC is a medical spray comprised of Artemisinin (6 mg/ml), Curcumin (20 mg/ml), Frankincense (=Boswellia) (15 mg/ml) and vitamin C (60 mg/ml) in micellar formulation for spray administration.
- Conditions
- COVID-19, Corona Virus Infection, SARS-CoV 2, Coronavirus
- Trial name
- NCT04382040
- Testing
- ArtemiC
- Where
- 4 sites in India, Israel
- Volunteers
- 50 people
- Sponsor
- MGC Pharmaceuticals d.o.o
COVID-19, SARS CoV 2 Infection
Phase 3 Boosting Study for the SARS-CoV-2 rS Variant Vaccines
This is a Multi-Part, Phase 3, randomized, observer-blinded study to evaluate the safety and immunogenicity of booster doses of Omicron subvariant severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) recombinant (r) spike…
- Trial name
- COVID-19 (NCT05372588)
- Testing
- NVX-CoV2515, NVX-Cov2373, NVX-CoV2373 + NVX-CoV2515
- Where
- 19 sites in Australia
- Volunteers
- 1,340 people, healthy volunteers welcome
- Sponsor
- Novavax
SARS CoV 2 Infection
A Study of EDP-235 in Healthy Subjects
This study is a randomized, double-blind, placebo-controlled study. It will assess the safety, tolerability, and pharmacokinetics of orally administered single and multiple doses of EDP-235 in healthy adult subjects.
- Trial name
- NCT05246878
- Testing
- EDP-235
- Where
- United States
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- Enanta Pharmaceuticals, Inc
Severe Acute Respiratory Syndrome Coronavirus 2
Metformin Glycinate, Treatment of Patients With COVID-19 and Severe Acute Respiratory Syndrome Secondary to SARS-CoV-2.
The purpose of this study is to evaluate the efficacy and safety of the metformin glycinate and standard treatment of the hospital in hospitalized patients with Severe Acute Respiratory Syndrome secondary to SARS-CoV2.
- Trial name
- DMMETCOV19-2 (NCT04625985)
- Testing
- Metformin Glycinate
- Where
- Mexico
- Volunteers
- 20 people
- Sponsor
- Laboratorios Silanes S.A. de C.V.
COVID-19, COVID-19 Pandemic
Accelerating COVID-19 Clinical Recovery in the Outpatient Setting: Retrospective Analysis
The purpose of this retrospective study is to evaluate the effectiveness of CPM nasal spray as part of the treatment of COVID-19 and its impact on clinical symptoms. Two cohort groups will be compared (CPM vs. standard care).
- Conditions
- COVID-19, COVID-19 Pandemic, COVID-19 Respiratory Infection, SARS CoV 2 Infection
- Trial name
- ACCROS-R (NCT05520944)
- Testing
- ClorNovir® (Chlorpheniramine) 0.4% Nasal Spray
- Where
- Dominican Republic
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- Dr. Ferrer BioPharma
COVID-19, SARS-CoV-2
Safety, Reactogenicity, and Immunogenicity Trial of CV2CoV mRNA Vaccine Against SARS-CoV-2 in Seropositive Adult Participants
Prevention of COVID-19 caused by SARS-CoV-2.
- Trial name
- NCT05260437
- Testing
- CV2CoV (2 µg), CV2CoV (4 µg), CV2CoV (8 µg)
- Where
- 24 sites in United States
- Volunteers
- 99 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
SARS-CoV Infection
VERU-111 in the Treatment of SARS-Cov-2 Infection by Assessing Its Effect on the Proportion of Patients Who Die on Study
To demonstrate the efficacy of VERU-111 in the treatment of SARS-Cov-2 Infection by assessing its effect on the proportion of patients who die on study (prior to Day 60).
- Trial name
- VERU-111 (NCT04842747)
- Testing
- VERU-111
- Where
- 58 sites in United States, Argentina and 4 more
- Volunteers
- 204 people
- Sponsor
- Veru Inc.
SARS CoV 2 Infection
Study to Evaluate Safety, Tolerability, Efficacy and Pharmacokinetics of ASC10 in Mild to Moderate COVID-19 Patients
This is a phase Ib, randomized, double-blind, placebo-controlled study to evaluate safety, tolerability, efficacy and pharmacokinetics of ASC10 tablets in mild or moderate COVID-19 subjects.
- Trial name
- NCT05596045
- Testing
- ASC10
- Where
- 2 sites in United States
- Sponsor
- Ascletis Pharmaceuticals Co., Ltd.
COVID-19, Coronavirus
A Study to Assess Pulsed Inhaled Nitric Oxide vs Placebo in Subjects With Mild or Moderate COVID-19
A randomized, double-blind, placebo-controlled study to assess the efficacy and safety of pulsed inhaled iNO compared to placebo in subjects with COVID-19.
- Conditions
- COVID-19, Coronavirus, Coronavirus Infection
- Trial name
- COViNOX (NCT04421508)
- Testing
- INOpulse
- Where
- 17 sites in United States
- Volunteers
- 191 people
- Sponsor
- Bellerophon Pulse Technologies
Infections, Respiratory, Virus Diseases
A Trial Investigating the Safety and Effects of Four BNT162 Vaccines Against COVID-19 in Healthy and Immunocompromised Adults
Originally, the study was planned to include two parts, i.e., Part A and Part B, however Part B was cancelled due to changes in the overall clinical development plan.
- Conditions
- Infections, Respiratory, Virus Diseases, Infection Viral, Vaccine Adverse Reaction
- Trial name
- NCT04380701
- Testing
- BNT162a1, BNT162b1, BNT162b2
- Where
- 5 sites in Germany
- Volunteers
- 512 people, healthy volunteers welcome
- Sponsor
- BioNTech SE
Covid19, SARS CoV 2 Infection
Safety and Immunogenicity Study of Recombinant Protein RBD Candidate Vaccine Against SARS-CoV-2 in Adult Healthy Volunteers (COVID-19)
This is a first-in-human, phase I/IIa, randomized, controlled, observer-blinded, dose-escalation, multicentre clinical trial to evaluate safety and immunogenicity of COVID-19 HIPRA vaccine in adult healthy volunteers.
- Trial name
- NCT05007509
- Testing
- COVID-19 vaccine HIPRA 10, COVID-19 vaccine HIPRA 20, COVID-19 vaccine HIPRA 40
- Where
- 2 sites in Spain
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Laboratorios Hipra, S.A.
Healthy Participants
Food Effect Study to Evaluate the Effect of High-Fat Meal on the Relative Bioavailability of PF-07321332 Boosted With Ritonavir in Healthy Adult Participants
This is a Phase 1, open label, single dose, randomized, 2-treatment, 2-sequence, 2-period crossover study to evaluate the effect of high-fat meal on the relative bioavailability of PF-07321332 boosted with ritonavir following…
- Trial name
- NCT05129475
- Testing
- PF-07321332/ritonavir, Ritonavir
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Pfizer
SARS CoV 2 Infection
Study to Evaluate Safety, Tolerability, Pharmacokinetics and the Food Effect on PK of ASC10 Tablets in Healthy Subjects
This is a phase I, randomized, double-blind, placebo-controlled study to evaluate safety, tolerability, and pharmacokinetics of ASC10 tablets and an open-label, crossover design to evaluate the food effect on PK of ASC10 in…
- Trial name
- NCT05523141
- Testing
- ASC10
- Where
- China
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- Ascletis Pharmaceuticals Co., Ltd.
COVID-19, SARS CoV 2 Infection
Immunogenicity and Safety of ChulaCov19 BNA159 and ChulaCov19 BNA159.2 Vaccines as a Booster Dose in Adults
This clinical trial is designed to assess the safety, tolerability and immunogenicity of a single dose of ChulaCov19 BNA159 and ChulaCov19 BNA159.2 vaccines as a booster dose, given at least 3 months after receipt of a previous…
- Trial name
- NCT05605470
- Testing
- ChulaCov19 BNA159 vaccine (50 mcg), Pfizer/BNT vaccine (30 mcg), COMVIGEN (ChulaCov19 BNA159.2) vaccine (50 mcg)
- Where
- 5 sites in Australia
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Technovalia, Pty Ltd
SARS CoV 2 Infection
A Phase IIb/III Clinical Trial to Assess Safety and Immunogenicity of a COVID-19 Vaccine Booster Dose in Immunosupressed Adults.
A phase IIb/III, open label, single arm, multi-centre, trial to assess the immunogenicity and safety of an additional dose vaccination with a recombinant protein RBD fusion heterodimer candidate (PHH-1V) against SARS-CoV-2, in…
- Trial name
- NCT05303402
- Testing
- PHH-1V
- Where
- 6 sites in Spain, Turkey (Türkiye)
- Volunteers
- 241 people
- Sponsor
- Hipra Scientific, S.L.U